leadf
logo-loader
viewPharmaxis Ltd

Pharmaxis boosts cash balance with US$7 million milestone payment from US licensee Chiesi following FDA approval of Bronchitol®

Pharmaxis is now advancing clinical development of a new cancer drug.

Pharmaxis Ltd - Pharmaxis boosts cash balance with US$7 million milestone payment from US licensee Chiesi following FDA approval of Bronchitol®
Another US$3 million cash milestone payment from Chiesi is expected next quarter.

Pharmaxis Ltd (ASX:PXS) has boosted its cash balance after receiving a US$7 million (~A$9.2 million) milestone payment from US licensee Chiesi Farmaceutici S.p.A. and is well-funded to progress the development of innovative medicines with high patient need.

This payment follows the recent approval by the US Food Drug Administration of Bronchitol® (mannitol) for the treatment of adult cystic fibrosis patients in the US.

Shares have been as much as 14% higher to an intra-day high of 9.9 cents 

Further US$3 million in Q1

A further US$3 million is payable by Chiesi on shipment by Pharmaxis of commercial launch stock, and this is scheduled for the first quarter of 2021.

The milestone payment from Chiesi follows an R&D tax incentive of A$5 million in October and with cash funds of $A10 million as of September 30, 2020, the company has a strong balance sheet to support its clinical work as it heads into the New Year.

“Transformational” approval

US FDA approval for Bronchitol® cystic fibrosis treatment has been labelled by chief executive officer Gary Phillips as being “transformational” for Pharmaxis.

He said: “The FDA still remains the gold standard by which all biotechs judge their success and the eventual quality of their programs and I’m pleased to say that Bronchitol is our second approval with the FDA.

“The approval brings US$10 million of cash milestones into the company.

“We have a long-term agreement with an international partner Chiesi in the US who expect sales to commence in the first half of next year.

New cancer drug with unique mechanism

The company is quickly moving to clinical development of its drug candidate PXS-5505 which has demonstrated a unique mechanism of action that has the potential for disease modification of the rare bone marrow cancer myelofibrosis.

It is a pan-LOX inhibitor that seeks to reverse the bone marrow fibrosis that drives morbidity and mortality in the disease.

PXS-5505 was patented in 2018, and the company has moved swiftly through the early development stages due to its potential.

Phase 2 study

Phillips said: “We’ve completed the long-term safety and toxicity studies, we’ve already completed a phase one study in healthy volunteers, we’ve demonstrated the product is safe, and importantly, we’ve already been to the FDA.

“The FDA granted the drug orphan status in July and after submitting all our data to date to secure IND approval – the FDA gave us permission to go out and start a phase two study in patients.

“We aim to start in quarter one of 2021, progressing an open label study recruiting up to 42 patients with myelofibrosis in Australia and international sites.”

Quick facts: Pharmaxis Ltd

Price: 0.082 AUD

ASX:PXS
Market: ASX
Market Cap: $32.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Pharmaxis enrols first patient in its bone marrow cancer trial

Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips discusses with Proactive's Andrew Scott the news they've enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis. The trial aims to demonstrate that PXS‐5505, the...

1 week, 1 day ago

3 min read